Researchers have been delving into the effects of GLP-1 agonists, a class of medications initially designed to manage type 2 diabetes. The burgeoning interest in these drugs stems from their potential benefits and minimal negative side effects. Originally used for diabetes, these medications have gained popularity for weight loss, prompting a comprehensive study of their broader implications.
A significant study, maintained by the U.S. Department of Veterans Affairs, analyzed medical records from over 2 million individuals on diabetes medications, including more than 215,000 who used GLP-1 drugs. Conducted from October 2017 through December 2023, this research aimed to uncover the full spectrum of health outcomes associated with GLP-1 agonists. Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis, led the study, which examined 175 potential health effects.
“We saw skyrocketing utilization of GLP-1s, and we saw a few reports investigating one outcome or another,” – Ziyad Al-Aly, MD
The study's findings confirm clinical observations that GLP-1 agonists can be beneficial for numerous conditions beyond weight loss. Dr. Babak Firoozi expressed surprise and encouragement at the medication's positive impact on reducing cognitive decline risk, emphasizing that safety remains crucial as usage expands.
“I was surprised and encouraged about all the positive impact the medication has on patients, specifically in reducing risk of cognitive decline. It is becoming clear that the benefits of these medications go beyond weight loss and diabetes control. And, of course, safety is important as more and more indications to use this group of medications arise. The negative effects seem minimal.” – Babak Firoozi, MD
The study has revealed that GLP-1 agonists might reduce neuroinflammation and influence brain centers responsible for impulse control and reward signaling. Dr. Al-Aly noted these mechanisms could impact neuropsychiatric conditions, supporting earlier research showing GLP-1 receptors in the brain.
“GLP-1 reduces neuroinflammation and also affects centers in the brain that are responsible for impulse control and reward signaling — there are many studies showing that we indeed have GLP-1 receptors in our brain. These are likely mechanisms by which GLP-1 may impact neuropsychiatric conditions.” – Ziyad Al-Aly, MD
Moreover, GLP-1 agonists offer promise for those seeking to address multiple health issues simultaneously. Dr. Al-Aly highlighted their potential to aid individuals with obesity who also wish to quit smoking, addressing both conditions at once.
“I think there is clearly (an) added benefit for several conditions. For example, a person with obesity who also wants to quit smoking — getting GLP-1 may help that person hit two birds (with) one stone — simultaneously addressing obesity and also help them quit smoking. Clearly, the added benefits are welcome news,” – Ziyad Al-Aly, MD
Despite their benefits, taking GLP-1 medications without proper nutritional education could pose risks. Experts like Kipnis caution against neglecting dietary habits while on these drugs, as improper nutrition may lead to gastrointestinal and renal issues.
“This study confirms what we are seeing clinically. People with real weight loss are happier overall. They feel empowered that they can finally control their weight. Decreased obesity has long been linked with less inflammation in every body system. GI problems and renal problems will always be seen if people are not eating correctly and maintaining hydration. If you take these medications without nutritional education, they can be harmful,” – Kipnis
Leave a Reply